Potential of Imiquimod and Fulvestrant against Mycobacterium tuberculosis using Molecular docking approach

Mycobacterium Tuberculosis cause severe disease of lungs known as Tuberculosis. It is a major cause of morbidity and mortality even in the emerging countries also. However, to prepare an antibiotics drug against Mycobacterium tuberculosis is a major challenge. Two compounds Imiquimod, Fulvestrant were selected for our study which can stop action of Arbinosyl transferase enzyme of M.tuberculosis. In silico docking was carried out by using software named swissdock (http://www.swissdock.ch/). These are computer aided drug designing techniques which are helpful for this study. Both the above 2 drugs have the potential to block the activity of mutant strain of M.tuberculosis.